SDZ ENA 713 blocker of acetylcholine breakdown: Began recruiting for a worldwide Phase III trial in 2,400 patients with mild to moderate, probable Alzheimer's d

Sandoz Pharma Ltd., Basel Product: SDZ ENA 713 blocker of acetylcholine breakdown Indication: Alzheimer's disease Status: Began recruiting for a worldwide Phase III trial in 2,400 patients with mild t...